These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34906272)

  • 1. Tumor Antigen-Based Nanovaccines for Cancer Immunotherapy: A Review.
    Zhao J; Du G; Sun X
    J Biomed Nanotechnol; 2021 Nov; 17(11):2099-2113. PubMed ID: 34906272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Biomimetic Autophagosomes-Based Nanovaccine Boosts Anticancer Immunity.
    Qu L; Cui G; Sun Y; Ye R; Sun Y; Meng F; Wang S; Zhong Z
    Adv Mater; 2024 Oct; 36(40):e2409590. PubMed ID: 39194369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy.
    Mao L; Ma P; Luo X; Cheng H; Wang Z; Ye E; Loh XJ; Wu YL; Li Z
    ACS Nano; 2023 Jun; 17(11):9826-9849. PubMed ID: 37207347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy.
    Liu M; Feng Y; Lu Y; Huang R; Zhang Y; Zhao Y; Mo R
    Sci Adv; 2024 Mar; 10(11):eadk2444. PubMed ID: 38478602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanovaccines: An effective therapeutic approach for cancer therapy.
    Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
    Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanovaccine-Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy.
    Qin L; Zhang H; Zhou Y; Umeshappa CS; Gao H
    Small; 2021 Jul; 17(28):e2006000. PubMed ID: 33768693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
    Yip T; Qi X; Yan H; Chang Y
    ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
    Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
    ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node-targeting nanovaccines for cancer immunotherapy.
    Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
    J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanobiomaterial-based vaccination immunotherapy of cancer.
    Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
    Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanovaccines: Immunogenic tumor antigens, targeted delivery, and combination therapy to enhance cancer immunotherapy.
    Jahanafrooz Z; Oroojalian F; Mokhtarzadeh A; Rahdar A; Díez-Pascual AM
    Drug Dev Res; 2024 Aug; 85(5):e22244. PubMed ID: 39138855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy.
    Tian R; Ke C; Rao L; Lau J; Chen X
    Adv Drug Deliv Rev; 2020; 161-162():145-160. PubMed ID: 32827558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial outer membrane vesicle-based cancer nanovaccines.
    Gao X; Feng Q; Wang J; Zhao X
    Cancer Biol Med; 2022 Sep; 19(9):1290-300. PubMed ID: 36172794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
    Wang QT; Liu YX; Wang J; Wang H
    ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection.
    Xu F; Yuan Y; Wang Y; Yin Q
    Biomed Pharmacother; 2023 Feb; 158():114117. PubMed ID: 36528914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.